Bruno Mendonça Protásio
Research Subjects
Research Interests
Bruno Mendonça Protásio has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Dias de Moraes
Oncoclinicas, Div Gastrointestinal Med Oncol, Salvador, Brazil
2 shared publications Jorge Sabbaga
IDOR- Intituto D'Or de Pesquisa e Ensino, Sao Paulo, Brazil; Disciplina de Oncologia Clínica do Departamento de Radiologia e Oncologia da Faculdade de Medicina da Universidade de São Paulo- FMUSP. Instituto do Câncer do Estado de São Paulo- ICESP, Sao Paulo, Brazil
2 shared publications- Marco Antonio Oliveira Lessa
Hospital Santa Izabel, Santa Casa de Misericordia da Bahia, Salvador, Bahia, Brazil
2 shared publications Paulo M. Hoff
IDOR- Intituto D'Or de Pesquisa e Ensino, Sao Paulo, Brazil; Disciplina de Oncologia Clínica do Departamento de Radiologia e Oncologia da Faculdade de Medicina da Universidade de São Paulo- FMUSP. Instituto do Câncer do Estado de São Paulo- ICESP, Sao Paulo, Brazil
2 shared publications- Adriana Kahn
Yale Cancer Center, Yale School of Medicine, New Haven, CT
1 shared publication - Alexandre Farias de Albuquerque
Liga Bahiana Contra o Câncer, Hospital Aristides Maltez, Salvador, Bahia, Brazil
1 shared publication
Latest Publications
- 9 December 2023
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 23 (1) , 73-84
Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort
- 9 December 2023
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 23 (1) , 73-84
Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort
- Open Access
- 1 December 2023
- Published by Georg Thieme Verlag KG in Journal of Coloproctology
- Vol. 43 (S 01) , S1-S270
QUIMIORRADIOTERAPIA NEOADJUVANTE SEGUIDA DE QUIMIOTERAPIA DE CONSOLIDAÇÃO PARA CÂNCER DE RETO cT2N1M0, cT3N0M0 E cT3N1M0: UMA COORTE RETROSPECTIVA
Amanda.r.ferreira@hotmail.com Introdução Há controvérsia na literatura a respeito do regime de tratamento neoadjuvante de escolha para pacientes (pts) com câncer de reto localmente avançado (CRLA). Embora a terapia neoadjuvante total (TNT) seja uma opção padrão de tratamento nos pts nos estágios clínicos cT3/cT4 ou com linfonodo positivo, o estudo PROSPECT (Schrag et al., NEJM 2023) demonstrou que a maioria dos pts com estadiamento cT2N1M0, cT3N0M0 e cT3N1M0 poderia ser tratada com quimioterapia perioperatória sem prejuízo oncológico. Objetivo Avaliar o impacto da TNT nos pts com CRLA e estadiamento cT2N1, cT3N0 e cT3N1 tratados na comunidade. Materiais e Métodos Realizou-se um estudo de coorte retrospectiva em Salvador, Bahia, de maio de 2020 a junho de 2023. Eram elegíveis todos os pacientes adultos consecutivos com adenocarcinoma do reto tratados com TNT com pelo menos uma sessão de radioterapia e/ou um ciclo de quimioterapia neoadjuvante. Foram incluídos apenas pts com estadiamento cT2N1M0, cT3N0M0 e cT3N1M0 e tratados com regime de quimiorradioterapia concomitante de curso longo seguida de quimioterapia de consolidação. Todos os pacientes foram estadiados com ressonância magnética de reto. O desfecho primário foi taxa de resposta clínica completa (cRC) ao final da TNT. Resultados Foram incluídos 21 pacientes com idade mediana de 62 (amplitude: 33 a 77) anos sendo que 11 pts (52%) eram do sexo masculino. De acordo com a 8ª edição do manual do AJCC, 6 pts (29%) eram EC II, e 15 (71%), EC III. Ao todo, 10 pts (48%) apresentaram tumor distando ≤ 5cm da borda anal (BA), e 11 pts (52%) apresentaram tumor distando entre 5 cm e 10 cm. Ao tempo desta análise, 15 pts apresentaram dados de reestadiamento após a conclusão da TNT. Entre eles, o tempo mediano entre o término da fase de quimiorradioterapia concomitante e o reestadiamento foi de 6,1 (amplitude: 5,0 a 14,5) meses. Ao todo, 6/15 pts apresentaram uma taxa de cRC de 40% (IC95%: 20% a 64%) ao final da TNT. Conclusão Os dados iniciais apontam que a TNT é uma modalidade de tratamento efetiva nos pts com CRLA e estadiamento cT2N1M0, cT3N0M0 e cT3N1M0 tratados na comunidade. Article published online: 27 February 2024 © 2024. Sociedade Brasileira de Coloproctologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 1 December 2023
- Published by Georg Thieme Verlag KG in Journal of Coloproctology
- Vol. 43 (S 01) , S1-S270
Open AccessQUIMIORRADIOTERAPIA NEOADJUVANTE SEGUIDA DE QUIMIOTERAPIA DE CONSOLIDAÇÃO PARA CÂNCER DE RETO cT2N1M0, cT3N0M0 E cT3N1M0: UMA COORTE RETROSPECTIVA
Amanda.r.ferreira@hotmail.com Introdução Há controvérsia na literatura a respeito do regime de tratamento neoadjuvante de escolha para pacientes (pts) com câncer de reto localmente avançado (CRLA). Embora a terapia neoadjuvante total (TNT) seja uma opção padrão de tratamento nos pts nos estágios clínicos cT3/cT4 ou com linfonodo positivo, o estudo PROSPECT (Schrag et al., NEJM 2023) demonstrou que a maioria dos pts com estadiamento cT2N1M0, cT3N0M0 e cT3N1M0 poderia ser tratada com quimioterapia perioperatória sem prejuízo oncológico. Objetivo Avaliar o impacto da TNT nos pts com CRLA e estadiamento cT2N1, cT3N0 e cT3N1 tratados na comunidade. Materiais e Métodos Realizou-se um estudo de coorte retrospectiva em Salvador, Bahia, de maio de 2020 a junho de 2023. Eram elegíveis todos os pacientes adultos consecutivos com adenocarcinoma do reto tratados com TNT com pelo menos uma sessão de radioterapia e/ou um ciclo de quimioterapia neoadjuvante. Foram incluídos apenas pts com estadiamento cT2N1M0, cT3N0M0 e cT3N1M0 e tratados com regime de quimiorradioterapia concomitante de curso longo seguida de quimioterapia de consolidação. Todos os pacientes foram estadiados com ressonância magnética de reto. O desfecho primário foi taxa de resposta clínica completa (cRC) ao final da TNT. Resultados Foram incluídos 21 pacientes com idade mediana de 62 (amplitude: 33 a 77) anos sendo que 11 pts (52%) eram do sexo masculino. De acordo com a 8ª edição do manual do AJCC, 6 pts (29%) eram EC II, e 15 (71%), EC III. Ao todo, 10 pts (48%) apresentaram tumor distando ≤ 5cm da borda anal (BA), e 11 pts (52%) apresentaram tumor distando entre 5 cm e 10 cm. Ao tempo desta análise, 15 pts apresentaram dados de reestadiamento após a conclusão da TNT. Entre eles, o tempo mediano entre o término da fase de quimiorradioterapia concomitante e o reestadiamento foi de 6,1 (amplitude: 5,0 a 14,5) meses. Ao todo, 6/15 pts apresentaram uma taxa de cRC de 40% (IC95%: 20% a 64%) ao final da TNT. Conclusão Os dados iniciais apontam que a TNT é uma modalidade de tratamento efetiva nos pts com CRLA e estadiamento cT2N1M0, cT3N0M0 e cT3N1M0 tratados na comunidade. Article published online: 27 February 2024 © 2024. Sociedade Brasileira de Coloproctologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 36, e1743
EARLY POSTOPERATIVE OUTCOMES OF THE ESOPHAGECTOMY MINIMALLY INVASIVE IN ESOPHAGEAL CANCER
BACKGROUND: The incidence of esophageal cancer is high in some regions and the surgical treatment requires reference centers, with high volume, to make surgery feasible. AIMS: To evaluate patients undergoing minimally invasive esophagectomy by thoracoscopy in prone position for the treatment of esophageal cancer and to recognize the experience acquired over time in our service after the introduction of this technique. METHODS: From January 2012 to August 2021, all patients who underwent the minimally invasive esophagectomy for esophageal cancer were retrospectively analyzed. In order to assess the factors associated with the predefined outcomes as fistula, pneumonia, and intrahospital death, we performed univariate and multivariate logistic regression analyses, accounting for age as an important factor. RESULTS: Sixty-six patients were studied, with mean age of 59.5 years. The main histological type was squamous cell carcinoma (81.8%). The incidence of postoperative pneumonia and fistula was 38% and 33.3%, respectively. Eight patients died during this period. The patient's age, T and N stages, the year the procedure was performed, and postoperative pneumonia development were factors that influenced postoperative death. There was a 24% reduction in the chance of mortality each year, associated with the learning curve of our service. CONCLUSIONS: The present study presented the importance of the team's experience and the concentration of the treatment of patients with esophageal cancer in reference centers, allowing to significantly improve the postoperative outcomes.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 36, e1743
Open AccessEARLY POSTOPERATIVE OUTCOMES OF THE ESOPHAGECTOMY MINIMALLY INVASIVE IN ESOPHAGEAL CANCER
BACKGROUND: The incidence of esophageal cancer is high in some regions and the surgical treatment requires reference centers, with high volume, to make surgery feasible. AIMS: To evaluate patients undergoing minimally invasive esophagectomy by thoracoscopy in prone position for the treatment of esophageal cancer and to recognize the experience acquired over time in our service after the introduction of this technique. METHODS: From January 2012 to August 2021, all patients who underwent the minimally invasive esophagectomy for esophageal cancer were retrospectively analyzed. In order to assess the factors associated with the predefined outcomes as fistula, pneumonia, and intrahospital death, we performed univariate and multivariate logistic regression analyses, accounting for age as an important factor. RESULTS: Sixty-six patients were studied, with mean age of 59.5 years. The main histological type was squamous cell carcinoma (81.8%). The incidence of postoperative pneumonia and fistula was 38% and 33.3%, respectively. Eight patients died during this period. The patient's age, T and N stages, the year the procedure was performed, and postoperative pneumonia development were factors that influenced postoperative death. There was a 24% reduction in the chance of mortality each year, associated with the learning curve of our service. CONCLUSIONS: The present study presented the importance of the team's experience and the concentration of the treatment of patients with esophageal cancer in reference centers, allowing to significantly improve the postoperative outcomes.
- 1 March 2017
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 16 (1) , 65-72
Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community
- 1 March 2017
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 16 (1) , 65-72
Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community
- 2 August 2014
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 120 (2) , 399-403
Antiepileptic drug prophylaxis in primary brain tumor patients: is current practice in agreement to the consensus?
The role of antiepileptic drugs (AED) prophylaxis in primary brain tumor (PBT) seizure-naïve patients remains unclear. Additionally, AED are associated with severe side effects, negative impact on cognition and drug interactions. Little is known about current practice regarding prophylactic AED use in PBT. We investigated its use in a tertiary care cancer center. We reviewed medical records of 260 patients registered in our center between 2008 and 2012, focusing on prophylactic AED use. A descriptive analysis was performed with SPSS IBM version 20.0. Median age was 44.5 years (11–83). Most patients had ECOG PS ≤1 (76.4 %). Among 141 seizure-naïve patients, 70.2 % received an AED as primary prophylaxis (PP). Most commonly used drugs as PP were phenytoin (85.9 %), carbamazepine (6.1 %) and phenobarbital (5.1 %). In only 14 patients (14.1 %) AEDs were eventually discontinued, in a median time of 5.9 months (1.1–76.8 m). AED were used as PP in 60 % of low-grade gliomas, 73.3 % of anaplastic gliomas and 93.9 % of glioblastoma patients. Twenty-seven patients (27.3 %) on PP presented seizures, generally associated with tumor progression. Of the 42 seizure-naïve patients not receiving AED prophylaxis, only two presented seizures, which occurred during or within the first week post-radiotherapy. In this cross-sectional study, prophylactic AED use in PBT was extremely high. Postoperatively, AED were discontinued in a minority of patients, mostly after a prolonged period. Current prophylactic AED use patterns in PBT are not in accordance with established guidelines.
- 2 August 2014
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 120 (2) , 399-403
Antiepileptic drug prophylaxis in primary brain tumor patients: is current practice in agreement to the consensus?
The role of antiepileptic drugs (AED) prophylaxis in primary brain tumor (PBT) seizure-naïve patients remains unclear. Additionally, AED are associated with severe side effects, negative impact on cognition and drug interactions. Little is known about current practice regarding prophylactic AED use in PBT. We investigated its use in a tertiary care cancer center. We reviewed medical records of 260 patients registered in our center between 2008 and 2012, focusing on prophylactic AED use. A descriptive analysis was performed with SPSS IBM version 20.0. Median age was 44.5 years (11–83). Most patients had ECOG PS ≤1 (76.4 %). Among 141 seizure-naïve patients, 70.2 % received an AED as primary prophylaxis (PP). Most commonly used drugs as PP were phenytoin (85.9 %), carbamazepine (6.1 %) and phenobarbital (5.1 %). In only 14 patients (14.1 %) AEDs were eventually discontinued, in a median time of 5.9 months (1.1–76.8 m). AED were used as PP in 60 % of low-grade gliomas, 73.3 % of anaplastic gliomas and 93.9 % of glioblastoma patients. Twenty-seven patients (27.3 %) on PP presented seizures, generally associated with tumor progression. Of the 42 seizure-naïve patients not receiving AED prophylaxis, only two presented seizures, which occurred during or within the first week post-radiotherapy. In this cross-sectional study, prophylactic AED use in PBT was extremely high. Postoperatively, AED were discontinued in a minority of patients, mostly after a prolonged period. Current prophylactic AED use patterns in PBT are not in accordance with established guidelines.